MBC Applying New Developments

CE / CME

Applying the Latest Developments in Metastatic Breast Cancer Through Education of Healthcare Professionals, Patients, and Caregivers

Nurses: 1.50 Nursing contact hours

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: October 19, 2023

Expiration: October 18, 2024

Joyce O'Shaughnessy
Joyce O'Shaughnessy, MD

Activity

Progress
1
Course Completed

References

  1. National Cancer Institute; Surveillance, Epidemiology, and End Results Program. Cancer stat facts: female breast cancer. seer.cancer.gov/statfacts/html/breast.html. Accessed September 28, 2023.
  2. Breast Cancer Research Foundation. Black women and breast cancer: why disparities persist and how to end them. bcrf.org/blog/black-women-and-breast-cancer-why-disparities-persist-and-how-end-them. Accessed September 28, 2023.
  3. Vrdoljak E, Gligorov J, Wierinck L, et al. Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe. Breast. 2021;55:79-90.
  4. Ren JX, Gong Y, Ling H, et al. Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics. Breast Cancer Res Treat. 2019;173:225-237.
  5. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. v.4.2023. nccn.org. Accessed September 28, 2023.
  6. Stover DG. Seeking sensitivity and resisting resistance: learning from the CDK4/6 experience. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Breast Cancer—Metastatic: Abstracts Discussion 1.
  7. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386:942-950.
  8. Lu YS, Im SA, Colleoni M, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res. 2022;28:851-859.
  9. Neven P, Fasching PA, Chia S, et al. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Res. 2023;25:103.
  10. Goetz MP, Toi M, Huober J, et al. MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). Presented at: European Society for Medical Oncology Congress 2022; September 9-13, 2022. Abstract LBA15.
  11. Finn RS, Rugo HS, Dieras VC, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): analyses from PALOMA-2. J Clin Oncol. 2022;40(suppl 17):Abstract LBA1003.
  12. Kalinsky K, Layman RM, Kaufman PA, et al. postMONARCH: a phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy. J Clin Oncol. 2022;40(suppl 16):Abstract TPS1117.
  13. Lu YS, Bin Mohd Mahidin EI, Azim H, et al. Primary results from the randomized phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract GS1-10.
  14. Abemaciclib [prescribing information]. Indianapolis, IN: Lilly USA, LLC; 2023.
  15. Ribociclib [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2022.
  16. Palbociclib [prescribing information]. New York, NY: Pfizer Inc; 2022.
  17. Swain SM, Baselga J, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724-734.
  18. Swain SM, Miles D, Kim SB, et al; CLEOPATRA study group. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:519-530.
  19. Cortés J, Cescon DW, Rugo HS, et al; KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817-1828.
  20. Rugo HS, Cortes J, Cescon DW, et al. KEYNOTE-355: final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. Presented at: European Society for Medical Oncology Congress 2021; September 16-21, 2021. Abstract LBA16.
  21. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810-821.
  22. Pembrolizumab [prescribing information]. Rahway, NJ: Merck & Co., Inc; 2023.
  23. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523-533.
  24. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753-763.
  25. Robson M, Im SA, Senkus E, et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer. 2023;184:39-47.
  26. Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31:1526.
  27. Alpelisib [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2022.
  28. Turner NC, Oliveira M, Howell SJ, et al; CAPItello-291 Study Group. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388:2058-2070.
  29. Allouchery V, Beaussire L, Perdrix A, et al. Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients. Breast Cancer Res. 2018;20:40.
  30. Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40:3246-3256.
  31. Tung N, Robson M, Ventz S, et al. TRCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol. 2020;38:4274-4282.
  32. Jhaveri KL, Goldman JW, Hurvitz SA, et al. Neratinib plus fulvestrant plus trastuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial. J Clin Oncol. 2022;40(suppl 16):Abstract 1028.
  33. Dostarlimab [prescribing information]. Philadelphia, PA: GlaxoSmithKline LLC; 2023.
  34. André F, Ciruelos E, Rubovszky G, et al; SOLAR-1 Study Group. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380:1929-1940.
  35. André F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32:208-217.
  36. Anderson EJ, Mollon LE, Dean JL, et al. A systematic review of the prevalence and diagnostic workup of PIK3CA mutations in HR+/HER2- metastatic breast cancer. Int J Breast Cancer. 2020;2020:3759179.
  37. Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22:489-498.
  38. Chia S. Neven P, Ciruelos EM, et al. Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study. J Clin Oncol. 2023;41(suppl 16):Abstract 1078.
  39. Bardia A, Bidard FC, Neven P, et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: updated results by duration of prior CDK4/6i in metastatic setting. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract GS3-01.
  40. Mittal A, Molto Valiente C, Tamimi F, et al. Filling the gap after CDK4/6 inhibitors: novel endocrine and biologic treatment options for metastatic hormone receptor positive breast cancer. Cancers (Basel). 2023;15:2015.
  41. Elacestrant [prescribing information]. New York, NY: Stemline Therapeutics, Inc; 2023.
  42. Oliveira M, Pominchuck D, Nowecki Z, et al. Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: results of the randomized, multi-dose phase 2 SERENA-2 trial. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract GS3-02.
  43. Jhaveri KL, Wang HC, Ma CX, et al. Imlunestrant, an oral selective estrogen receptor degrader, in combination with abemaciclib with or without an aromatase inhibitor, in estrogen receptor-positive advanced breast cancer: Results from the phase 1a/b EMBER study. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract PD13-12.
  44. Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomized, open-label, multicentre, phase 3 trial. Lancet. 2023;[Epub ahead of print].
  45. Tolaney SM, Bardia A, Marmé F, et al. Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 1003.
  46. Bardia A, Hurvitz SA, Tolaney SM, et al; ASCENT Clinical Trial Investigators. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529-1541.
  47. Sacituzumab govitecan [prescribing information]. Foster City, CA: Gilead Sciences, Inc; 2023.
  48. Spring LM, Nakajima E, Hutchinson J, et al. Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities. Oncologist. 2021;26:827-834.
  49. Rugo HS, Tolaney SM, Loirat D, et al. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2022;8:98.
  50. Cortés J, Kim SB, Chung WP, et al; DESTINY-Breast03 Trial Investigators. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143-1154.
  51. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401:105-117.
  52. Modi S, Jacot W, Yamashita T, et al; DESTINY-Breast04 Trial Investigators. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9-20.
  53. Trastuzumab deruxtecan [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc; 2022.
  54. Swain SM, Nishino M, Lancaster LH, et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev. 2022;106:102378.
  55. Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. 2020;382:597-609.
  56. Freedman R, Ren S, Tayob N, et al. Translational Breast Cancer Research Consortium Trial 022: neratinib and trastuzumab-emtansine for HER2+ breast cancer brain metastases (BCBM). Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract PD7-03.
  57. Entrectinib [prescribing information]. South San Francisco, CA: Genentech, Inc; 2023.
  58. Larotrectinib [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2022.
  59. Selpercatinib [prescribing information]. Indianapolis, IN: Eli Lilly and Co; 2022.
  60. Bardia A, Juric D, Shimizu T, et al. Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial. Presented at: European Society for Medical Oncology Breast Cancer Virtual Congress 2021; May 5-8, 2021. Abstract LBA4.
  61. Sacituzumab govitecan [prescribing information]. Morris Plains, NJ: Immunomedics, Inc.; 2021.
  62. US Food and Drug Administration. FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer. www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-sacituzumab-govitecan-triple-negative-breast-cancer. Accessed August 3, 2021.
  63. Llombart-Cussac A, Perez-Garcia JM, Ruiz Borrego M, et al. Metformin (MET) for the prevention of alpelisib (ALP)-related hyperglycemia (HG) in PIK3CA-mutated, hormone receptor-positive (HR[+]) HER2-negative (HER2[-]) advanced breast cancer (ABC). Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract PD8-02.
  64. Baselga J, Cortés J, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109-119.
  65. Curigliano G, Mueller V, Borges V, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022;33:321-329.